To determine the biological effect of RALY on HCC progression, siRNAs (siRALY#1) were used to knockdown RALY; these molecules showed a significant capacity to manipulate RALY expression (Figure 1G). The gene discussed is RALY; the disease is hepatocellular carcinoma.